• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Ultragenyx Pharmaceutical (RARE) Valuation After Recent Share Price Weakness

    Simply Wall St·03/22/2026 00:20:57
    Listen to the news

    Ultragenyx Pharmaceutical (RARE) has drawn fresh investor attention after recent share price moves, with the stock closing at US$19.87 and sitting well below its 1 year and past 3 months performance levels.

    See our latest analysis for Ultragenyx Pharmaceutical.

    The recent weakness follows a much steeper 40.7% 90 day share price decline and a 49.3% 1 year total shareholder return loss, signaling fading momentum as investors reassess both growth prospects and risk around the pipeline and current products.

    If Ultragenyx's swings have you thinking about diversification, this could be a good time to look at other healthcare names using our screener for 35 healthcare AI stocks

    With Ultragenyx trading at US$19.87 against a US$54.25 analyst price target and carrying an intrinsic discount flag, investors may need to consider whether this severe pullback represents a genuine opportunity or whether the market is already discounting future growth.

    Most Popular Narrative: 69% Undervalued

    With Ultragenyx's fair value in the most followed narrative sitting at about $64 against a last close of $19.87, the valuation gap is wide and rooted in detailed revenue and margin forecasts.

    The modelled fair value is essentially unchanged, moving from about US$63.90 to about US$64.00 per share.

    The assumed net profit margin has risen significantly from about 0.73% to about 32.24%.

    Read the complete narrative.

    Want to see what kind of growth profile could justify that margin shift and fair value? The narrative focuses on rising revenues and a sharp earnings swing. Curious how those assumptions stack across years and across products? The full breakdown sets out the financial path behind that $64 figure.

    Result: Fair Value of $64 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, investors still need to weigh ongoing losses, with a net income loss of US$575 million, as well as the risk that regulatory setbacks could disrupt the late stage pipeline.

    Find out about the key risks to this Ultragenyx Pharmaceutical narrative.

    Another Take on Valuation

    The narrative fair value of about $64 leans heavily on future cash flows and margins, yet the current P/S ratio of 2.8x is above the 2.1x fair ratio, even though it sits well below the US Biotechs average of 10.8x and peer average of 15.1x. Is that gap a safety margin or a warning light?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:RARE P/S Ratio as at Mar 2026
    NasdaqGS:RARE P/S Ratio as at Mar 2026

    Next Steps

    With sentiment clearly mixed, between sharp share price losses and a wide fair value gap, it makes sense to look at the numbers yourself and decide quickly what side you are on. To help frame both the upside and the risks before you act, take a closer look at the 2 key rewards and 3 important warning signs.

    Looking for more investment ideas?

    If Ultragenyx has sharpened your focus on risk and opportunity, do not stop here. Broaden your watchlist now so you are not reacting after the fact.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.